Low-dose vaginal estrogen is safe to start in a 71-year-old woman, with no major risks to mortality, cardiovascular events, or cancer when used appropriately.
The evidence strongly supports that low-dose vaginal estrogen therapy has a favorable safety profile in postmenopausal women, including those over age 65, with no increased risk of thrombosis, stroke, myocardial infarction, or breast cancer. 1
Key Safety Evidence
Cardiovascular and Thrombotic Risk
The most reassuring finding is that low-dose vaginal estrogen maintains serum estradiol levels within the normal postmenopausal range, resulting in minimal systemic absorption 1. This translates to:
- No increased risk of venous thromboembolism (VTE) - multiple studies show neutral to reduced risk 1, 2, 3
- No increased cardiovascular disease or stroke risk - observational data actually suggests potential risk reduction 2, 4, 3
- No first-pass hepatic effect unlike oral estrogen, which avoids triggering clotting factor synthesis 1
A 2026 scoping review of 11 observational studies found effect estimates ranging from null to reduced risk for VTE (adjusted HR 0.68-1.06), MI (adjusted HR 0.52-0.83), and stroke (adjusted HR 0.68-0.96) 2.
Cancer Risk
There is no evidence of increased breast cancer risk with low-dose vaginal estrogen 1, 3, 5. The Women's Health Initiative Observational Study found no significant difference in invasive breast cancer between vaginal estrogen users and nonusers 3. Recent FDA updates have removed boxed warnings related to breast cancer for vaginal estrogen products, acknowledging their distinct safety profile from systemic hormone therapy 5.
For endometrial cancer, the 2006 Cochrane review of 19 studies found no significant difference in endometrial thickness, hyperplasia, or cancer with vaginal estrogen use 1. One-year studies showed no cases of endometrial hyperplasia or cancer 1.
Minor Risks to Discuss
The actual adverse effects are limited and minor:
- Vulvovaginal candidiasis (yeast infections) 1
- Vaginal bleeding or breast tenderness with higher doses that cause systemic absorption 1
- Local irritation or discharge from cream formulations 1
Important Caveats
Dose Matters
Use the lowest effective dose to minimize any systemic absorption 1. Low-dose options include:
- 10 µg estradiol vaginal tablets twice weekly 1
- Low-dose vaginal ring (changed every 3 months) 1
- Small amounts of vaginal cream (0.5 g or less) 1
Avoid systemic-dose vaginal estrogen (CEE 0.625-2.5 mg daily), which suppresses FSH/LH and has systemic effects 1.
Duration Considerations
Long-term endometrial safety data beyond 1 year are lacking 1. While this doesn't mean harm occurs, it represents an evidence gap. For women at higher endometrial cancer risk (late menopause, obesity), consider periodic transvaginal ultrasound surveillance 1.
Contraindications
The main absolute contraindication is active breast cancer, particularly in women on aromatase inhibitors, where even small estrogen increases could theoretically reduce drug efficacy 1. For breast cancer survivors not on aromatase inhibitors, shared decision-making with oncology is recommended 1.
Clinical Bottom Line
For a 71-year-old woman with bothersome genitourinary symptoms, low-dose vaginal estrogen is appropriate and safe. The 2022 NAMS guidelines explicitly state that for genitourinary syndrome of menopause not relieved by over-the-counter therapies, low-dose vaginal estrogen is recommended 6. Age over 65 or more than 10 years from menopause is relevant for systemic hormone therapy risks, but does not apply to low-dose vaginal preparations that lack systemic absorption 6.
Start with the lowest effective dose, counsel about minor local side effects, and reassure that major cardiovascular, thrombotic, and cancer risks are not supported by current evidence.